Recall Injury from Adriamycin
Authors: STEPHEN C. COHEN
Journal: Annals of Internal Medicine (1975)

Letters1 August 1975Recall Injury from AdriamycinSTEPHEN C. COHEN, M.D., NICHOLAS J. DIBELLA, M.D., JOHN C. MICHALAK, M.D.STEPHEN C. COHEN, M.D.Search for more papers by this author, NICHOLAS J. DIBELLA, M.D.Search for more papers by this author, JOHN C. MICHALAK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-83-2-232_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWe have recently seen a 63-year-old man with mixed cell Hodgkin's disease who has been receiving multiple agent chemotherapy for difficult-to-control retroperitoneal disease. One of the agents the patient has received is adriamycin. After extravasation of adriamycin, the patient developed an erythematous lesion at the extravasation site, which ultimately necrosed, ulcerated, and slowly began to heal at about 1½ months after the accident. After this incident the patient received multiple courses of nitrogen mustard and vinblastine without apparent difficulty. Two months after the extravasation of adriamycin (at a time when the wound seemed well on its way to healing), another...Reference1. DONALDSONGLICKWILBUR SJJ: Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 81:407-408, 1974 LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Department of Medicine Fitzsimons Army Medical Center Denver, CO 80240 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByStravasi iatrogeni: gestione terapeuticaZytostatikainduzierte ParavasateDoxorubicinTratamiento de las extravasaciones iatrogénicas de soluciones citotóxicas o hiperosmolaresStravaso iatrogeno di soluzioni citotossiche o iperosmolari. Trattamento terapeuticoExtravasations iatrogènes de solutés cytotoxiques ou hyperosmolaires. Prise en charge thérapeutiqueDoxorubicinMeasuresHistopathologic Features Seen with Radiation Recall or Enhancement EruptionsDoxorubicinRecall Phenomenon Following EpirubicinSoft-tissue Reconstruction Following Extravasation of Chemotherapeutic AgentsBasic fibroblast growth factor in retardation of doxorubicin extravasation injuryAlterations in Wound Healing Secondary to Infusion InjuryTraitement chirurgical des ulcérations cutanées liées à la chimiothérapie anticancéreuseCutaneous complications of chemotherapeutic agentsTreatment of tissue extravasation by antitumor agentsRadiotherapy and chemotherapy in combined clinical trials: Problems and promiseClinical correlations of adriamycin pharmacologyCellular effects of combined adriamycin and x-irradiation in human tumor cellsComplications of irradiation related to apparent drug potentiation by adriamycinDaunomycin, Adriamycin, and Recall EffectDAVID BAER, M.D., LEE S. WILKINSON, M.D.Doxorubicin (z.B. Doxorubicin „Ebewe“, Adriblastin®) 1 August 1975Volume 83, Issue 2Page: 232-232KeywordsChemotherapeutic agentsChemotherapyHodgkin lymphomaLesionsUlcers Issue Published: 1 August 1975 PDF DownloadLoading ...